Michael Mejia
@mikemejiamd
Followers
829
Following
4K
Statuses
3K
Chair, Department of Radiation Oncology University of Santo Tomas Hospital. Head and Neck Unit BCI Tweets are my own.
Manila City, National Capital
Joined May 2010
0
1
6
RT @EChrisDee: The @USTFMSofficial and #Philippine #Dental Association #oral #oncology seminar series 🇵🇭 Dr @MikeMejiaMD's introduction to…
0
3
0
Fantastic summary of MDT trials and directions in OMBC! Key question to our #bcsm #radonc #sbrt folks: DOES an oligometastatic state exist in breast cancer? @luisajacomina @IBCradiation @SFShaitelmanMD @CJTsaiMDPhD @drdavidpalma
🧵 SBRT in Oligometastatic Breast Cancer: What does the evidence show? A summary of key studies and their impact on survival. Let’s dive in! 👇 1/ What is Oligometastatic Breast Cancer (OMBC)? OMBC is an intermediate state between localized and widespread metastatic disease, characterized by limited metastases (typically ≤5). It’s a promising target for local therapies like SBRT (Stereotactic Body Radiotherapy).
1
0
4
Brilliant explanations below 👇
My brilliant med student asked me to explain correlation, causation, confounding &collider bias. I used the following ex… so sharing here in case anyone finds it helpful! PS -I have learned much from @dnunan79 @Catalogofbias - a great resource for EBM. hopefully he approves😅
0
0
0
RT @DBelardoMD: My brilliant med student asked me to explain correlation, causation, confounding &collider bias. I used the following ex… s…
0
1K
0
👏👏👏
In today’s @QuadShotNews and now on @IJROBP as pre-proof‼️ Excited to share our study on palliative RT for breast cancer @MDAndersonNews 💖RT is effective in palliating symptoms from LABC 💕More RT isn’t always better (or necessary?) 💘QOL is 🔑
0
0
1
Kudos to @NRGonc HN team led by @Qle_stanford and @sueyom for publishing HN004. Need to identify better treatment options for curable cisplatin ineligible #hncsm patients
Final results of NRG HN004 coming out in Lancet Oncology, press release to follow, RT/cetux results look relatively strong for cisplatin ineligible HNSCC
0
1
8
Need a more robust discussion to redefine patient selection for MDT as this is now a moving target. @CJTsaiMDPhD @_ShankarSiva @DrMLChua @VedangMurthy @drkevin_chua_lm
"Oligo"-no more! 🇨🇦ARREST phase I out now @IJROBP - @sueyom ➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy ➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. Congrats! 👏👏
0
0
5
@DrMLChua @ASCO @lynn_schuchter @ASCOPres @jrgralow @davisa20 @lillian_siu @herbloong @DrRoselleDG @DiahMartina2 @drkiwikate Congratulations buddy
0
0
1
Excellent work by my colleague @WarrenBacorro from @UST1611official and the GEC ESTRO on HN #radonc #brachytherapy
Just published online! GEC-ESTRO recommendations for #headandneckcancer #brachytherapy (interventional #radiotherapy): 2nd update with focus on HDR and PDR. 👉 Read the article:
0
0
1
Cisplatin still king in fit patients Important to properly select patients who are not cisplatin candidates But does avelumab really improve outcomes? (p=0.059) Important work nonetheless at #ESMO2024 in #hncsm Glad to see #radonc papers in #medonc meetings
Congrats to my friend @YG_TAO & GORTEC for this huge trial of IO in LA HNSCC Avelumab-cetuximab inferior to cisplatin CRT in fit patients but superior to cetuximab-RT for PFS in cisplatin ineligible population. #ESMO2024
0
2
5
Easy to understand talk with excellent synthesis. Kudos @VedangMurthy from @TataMemorial
@luisajacomina
@EChrisDee
@MichelleEalaMD
@DrMLChua
@drkevin_chua_lm
#ESTROAsia24
@VedangMurthy giving an elegant overview as always on role of pelvic node irradiation in #ProstateCancer Amazing how many trials @TataMemorial run for #GUCancers
@piet_ost @TylerSbrt @AmarUKishan @mikemejiamd @scserendipity1 @aleberlin2 @alison_tree @_ShankarSiva @a_dalpra
0
2
12
Stoked to see this published and to have someone like @luisajacomina on the PH #radonc scene
Our #radonc opinion on this month’s interesting Gray Zone case @IJROBP ⬇️ Thank you @AmyMorenoMD for the guidance and opportunity! 🌟🫶🏻 @MDAndersonNews
0
2
5
Expanding #hncsm #radonc #cancer horizons with colleagues from across the archipelago and the Pacific
Exciting discussions with @USTFMSofficial and @MSKCancerCenter multidisciplinary teams on how to expand access to #oral #oncology #cancer #care in the #Philippines 🇵🇭 🙏 Drs @MikeMejiaMD, @LuisaJacomina, Cherry Estilo, Gelo Militante, Ian Fernando, and Sandy Uy
0
2
6
@DrMLChua @DavidSherMD Absolutely agree 💯 Different sequences in MRI in NPC is underutilized and under appreciated, hence full potential of the examination isn’t realized.
0
0
2
🚨📸HN Rad Oncs - would you change your ADJ RT practice for INT RISK (close margin, < 1mm ENE, 2-4LN, +PNI/LVSI) HPV+OPC after ECOG 3311 long-term results after #ASCO24. Assuming no other de-escalation protocol available? (Had to redo the vote due to poor wording/choices 😃) @DrMLChua @drdavidpalma @DavidSherMD @KaramLab @JamesBatesMD @ChristinaChapMD @henson_md @ScottBratman @DanielMaMD @seanmmcbride @xrtGenomics @yaoyu_md @LChen_MD @RobertFerrisMD @HSkinnerMDPhD
0
0
1
I found this VGR by @Mat_Guc and colleagues from Zurich extremely informative and insightful. I highly encourage my #radonc colleagues to attend
Virtual Grand Rounds in Radiation Oncology Potentially Radiation-Oncology changing clinical trials from ASCO Annual Meeting 2024 Critical appraisal from Radiation Oncologists for Radiation Oncologists Wednesday July 3rd 5:00 – 5:30 p.m.
0
1
3
@DavidSherMD @yuanjamesrao As in everything in life, TIMING IS KEY. IO may be a game changer but it is apparent that we need to rethink treatment strategies like timing and volumes.
1
0
2
@DrMLChua @DavidSherMD @seanmmcbride Agree. While it seems that the Ph2 30-40Gy data shows promise, I think patient selection on the basis of biology is the cornerstone and cannot just put all patients (no matter how “homogeneous” they initially seem) in a single basket. The worst toxicity of RT is local recurrence
0
1
2
@EChrisDee @fredtingmd @NiuSanford @way2spy @MichelleEalaMD Misconceptions go beyond AEs I think. A lot of hesitations seem to stem from gossip. 😂
0
0
2
@fredtingmd @NiuSanford @way2spy @EChrisDee @MichelleEalaMD Multifaceted issues including preconceived misconceptions on both ends. Need a holistic assessment
0
0
2